A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Shandong Xinhua Pharmaceutical Company Limited develops, manufactures, and sells bulk pharmaceuticals, preparations, and chemical products in the People’s Republic of China, the Americas, Europe, and internationally. It offers antipyretic and analgesic, cardiovascular and cerebrovascular, anti-infective, and central nervous drugs under the Xinhua brand; and contract manufacturing services for active pharmaceutical ingredients and pharmaceutical intermediates, OTC, and generics. The company also provides ibuprofen bulk pharmaceutical products; and prepared Chinese herbal medicine for decoction, traditional Chinese medicine, chemical bulk drugs, chemical preparations, chemical raw materials, antibiotics, biochemical medicines, anesthetics, anti-psychotic drugs, pharmaceutical precursor chemicals, protein assimilation preparations, peptide hormones, medical toxic drugs, etc. In addition, it offers raw materials and intermediates; internet data services, internet sales, and internet information services for pharmaceuticals and medical devices; veterinary drugs and fodders; bulk pharmaceutical and intermediates; steroid system apis and intermediates; and chemical raw materials. Further, the company produces and sells chemical products; exports and imports goods and technologies; and designs medical projects. Additionally, it engages in the property management, nonresidential real estate and housing leasing activities; certification and import and export business; installation and testing of chemical equipment; and manufacture of mechanical and electrical equipment, nonstandard equipment, as well as production and hardware and electrical equipment, and electrical installations equipment and manufacture; and sale of controller switching equipment. The company was founded in 1943 and is based in Zibo, the People’s Republic of China.
Financial Summary
| Share Statistics | SHNXY | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $1,158.1 | $579.1 | 47% |
|
| Shares Out (Mil) | 101.4 | 43.0 | 63% |
|
| Institutional Ownership | 82.2% | 84.3% | 51% |
|
| Float (Mil) | 463.7 | 46.8 | 85% |
|
| Beta | -0.02 | 0.62 | 6% |
|
| Avg Daily Volume (000s) | 2 | 285 | 9% |
|
| Price Change (52-week) |
na | 63.8% | na |
|
| Growth | SHNXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 6.4% | 6.7% | 43% |
|
| Net Income (5yr) | (3.6%) | (1.4%) | 35% |
|
| EPS (5yr) | (5.6%) | 14.9% | 24 |
|
| Dividends (5yr) | (1.4%) | 0.0% | 53% |
|
| Cash Flow (5yr) | (1.8%) | (14.9%) | 63% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | SHNXY | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $1,268 | $272 | 54% |
|
| Net Income (TTM) (Mil) | $38 | ($11) | 53% |
|
| EPS (TTM) | $0.056 | ($0.500) | 42% |
|
| Operating Cash Flow (TTM) (Mil) | $59 | ($6) | 48% |
|
| Net Cash Flow (TTM) (Mil) | ($4) | $4 | 35% |
|
| Long-Term Debt (Q1) (Mil) | $137 | $7 | 47% |
|
| Enterprise Value (Q1) (Mil) | $1,080 | $522 | 42% |
|
| Valuation | SHNXY | Industry Median |
Percentile (All Stocks) |
|
| P/B | na | 2.73 | na |
|
| P/E | na | 20.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.2 | na |
|
| Ratios | SHNXY | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 18.0% | 65.9% | 18% |
|
| Net Margin | 3.0% | 0.7% | 42% |
|
| ROA | 2.9% | (24.6%) | 61% |
|
| ROE | 5.1% | (19.7%) | 44% |
|
| Liabilities to Assets | 38.3% | 35.5% | 29% |
|
| F-Score | na | 3 | na |
|
Shandong Xinhua Pharmaceutical Company Limited did not pass any screens on 7/31/2026.
